In conclusion, our data support the hypotheses that K17 shields tumor cells from CD8+ T cells and recruits tumor promoting CD163+ M2 macrophages, indicating that K17 fundamentally impacts the immune response to PDAC. The gene discussed is CD163; the disease is neoplasm.